NovoSeven

Type: Product
Name: NovoSeven
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

"Nanoparticles for Controlling Bleeding and Drug Delivery" in Patent Application Approval Process

By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week A patent application by the inventors Lavik, Erin (Cleveland Heights, OH); Shoffstall, Andrew (Cleveland Heights, OH); Ustin, Jeffrey (Cleveland, OH), filed on October 12, 2012, ... [Published Pharmacy Choice - Sep 11 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Update: China Biologic Acquires Additional Interest In Guizhou Facility - Shares Rise

By Trevor Lowenthal :Before Q2 earnings on August 5, I wrote a bullish article on China Biologic Products (NASDAQ: CBPO ), with a thesis stating that the company's plasma-based products should benefit from increasing market demand in China for Q2. I argued ... [Published BioPortfolio - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Update: China Biologic Acquires Additional Interest In Guizhou Facility - Shares Rise

Summary China Biologic acquires additional equity in the Guizhou Taibang Facility. Since this will likely lead to earnings accretion, I reiterate my bull thesis on China Biologic. This event came as a surprise, since I anticipated that funds from the ... [Published Seeking Alpha - Aug 26 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

NOVOSEVEN RT (Coagulation Factor Viia (Recombinant)) Kit [Novo Nordisk]

First reported Jul 07 2014 - Updated Jul 08 2014 - 1 reports

FDA Approves NovoSeven® RT for the Treatment of Glanzmann's Thrombasthenia (GT) With Refractoriness

PLAINSBORO, N.J., July 7, 2014 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) as the first recombinant treatment for bleeding episodes and perioperative ... [Published PR Newswire: Policy & Public Interest - Jul 07 2014]

Quotes

"A pharmaceutical composition comprising the nanoparticle of the disclosure is provided. In various aspects, the pharmaceutical composition is an intravenous administration formulation, a lyophilized formulation, or a powder."

More Content

All (8) | News (3) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
"Nanoparticles for Controlling Bleeding and Dru... [Published Pharmacy Choice - Sep 11 2014]
Update: China Biologic Acquires Additional Inte... [Published BioPortfolio - Aug 26 2014]
Update: China Biologic Acquires Additional Inte... [Published Seeking Alpha - Aug 26 2014]
NOVOSEVEN RT (Coagulation Factor Viia (Recombin... [Published DailyMed Drug Label Updates for the last seven ... - Aug 20 2014]
FDA Approves NovoSeven® RT for the Treatment of... [Published PR Newswire: Policy & Public Interest - Jul 07 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 03 2014]
Research and Markets: Novoseven RT (Hemophilia ... [Published Business Wire Professional Services News - Jan 31 2014]
Fact Sheet for Novo-Nordisk A/S [Published Able2Act - Jul 24 2008]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
NOVOSEVEN RT (Coagulation Factor Viia (Recombin... [Published DailyMed Drug Label Updates for the last seven ... - Aug 20 2014]
Updated Date: Aug 19, 2014 EST ...
FDA Approves NovoSeven® RT for the Treatment of... [Published PR Newswire: Policy & Public Interest - Jul 07 2014]
PLAINSBORO, N.J., July 7, 2014 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) as the first recombinant treatment for bleeding episodes and perioperative ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 03 2014]
Research and Markets: Novoseven RT (Hemophilia ... [Published Business Wire Professional Services News - Jan 31 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mf7sbv/novoseven_rt) has announced the addition of the "Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022" report to their offering. The competitive ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.